{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:08:43Z","timestamp":1785017323177,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":222,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.idcr.2021.e01254","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T11:09:36Z","timestamp":1628766576000},"page":"e01254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports"],"prefix":"10.1016","volume":"26","author":[{"given":"Alaaeldin","family":"Abdelmajid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wala","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Elhiday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqar","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna A.","family":"Al.Maslamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Zeyad","family":"Elmekaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idcr.2021.e01254_bib1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.idcr.2021.e01254_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006889","article-title":"Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase","volume":"14","author":"Jordan","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.idcr.2021.e01254_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/AAC.01814-20","article-title":"New perspectives on antimicrobial agents: Remdesivir treatment for COVID-19","volume":"65","author":"Aleissa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idcr.2021.e01254_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2014 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idcr.2021.e01254_bib5","unstructured":"Bhimraj A, Morgan R, Shumaker A, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Version 4.3.0. 2021. Available URL."},{"key":"10.1016\/j.idcr.2021.e01254_bib6","unstructured":"National Institutes of Health COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines; 2021. Available from: \u3008https:\/\/www.covid19treatmentguidelines.nih.gov\/about-the-guidelines\/whats-new\/\u3009."},{"key":"10.1016\/j.idcr.2021.e01254_bib7","unstructured":"Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569\u201378."},{"key":"10.1016\/j.idcr.2021.e01254_bib8","doi-asserted-by":"crossref","unstructured":"Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. doi:10.1056\/NEJMoa2015301.","DOI":"10.1056\/NEJMoa2015301"},{"issue":"5","key":"10.1016\/j.idcr.2021.e01254_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00233-21","article-title":"Anaphylaxis due to Remdesivir","volume":"65","author":"Hopkins","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idcr.2021.e01254_bib10","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idcr.2021.e01254_bib11","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of Remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idcr.2021.e01254_bib12","doi-asserted-by":"crossref","unstructured":"Attena E, Albani S, Maraolo AE, et al. Remdesivir-induced bradycardia in COVID-19: a single center prospective study. Circ Arrhythm Electrophysiol 2021.","DOI":"10.1161\/CIRCEP.121.009811"},{"issue":"10","key":"10.1016\/j.idcr.2021.e01254_bib13","first-page":"11132","article-title":"Cardiac adverse events with Remdesivir in COVID-19 infection","volume":"12","author":"Gupta","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.idcr.2021.e01254_bib14","doi-asserted-by":"crossref","unstructured":"Gubitosa J, Kakar P, Gerula C, at al. Marked sinus bradycardia associated with Remdesivir in COVID-19: a case and literature review. PMID: 33163977 PMCID: PMC7598346. doi: 10.1016\/j.jaccas.2020.08.025.","DOI":"10.1016\/j.jaccas.2020.08.025"},{"key":"10.1016\/j.idcr.2021.e01254_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00431-021-03940-4","article-title":"Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection","volume":"180","author":"Sanchez-Codez","year":"2021","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.idcr.2021.e01254_bib16","doi-asserted-by":"crossref","unstructured":"Jacinto JP, Patel M, Goh J, et al. Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease [published online ahead of print, 2021 May 15]. Heart Rhythm Case Rep 2021;10.1016\/j.hrcr.2021.05.004. doi:10.1016\/j.hrcr.2021.05.004.","DOI":"10.1016\/j.hrcr.2021.05.004"},{"issue":"5","key":"10.1016\/j.idcr.2021.e01254_bib17","doi-asserted-by":"crossref","first-page":"791.e5","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious bradycardia and Remdesivir for coronavirus 2019 (COVID-19): a new safety concerns","volume":"27","author":"Touafchia","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idcr.2021.e01254_bib18","series-title":"Braunwald\u2019s heart disease: a textbook of cardiovascular medicine","year":"2018"},{"key":"10.1016\/j.idcr.2021.e01254_bib19","article-title":"Severe sinus bradycardia induced by favipiravir","author":"Mhd Baraa Habib","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.idcr.2021.e01254_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006034","article-title":"QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient","volume":"11","author":"Chinello","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.idcr.2021.e01254_bib21","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.3201\/eid2610.202648","article-title":"Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan","volume":"26","author":"Ikeuchi","year":"2020","journal-title":"Emerg Infect Dis"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250921002109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250921002109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:04:47Z","timestamp":1761998687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250921002109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":21,"alternative-id":["S2214250921002109"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2021.e01254","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2021.e01254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e01254"}}